Table 1 Baseline characteristics
| Â | Alfacalcidol-paricalcitol | Paricalcitol-alfacalcidol |
|---|---|---|
n = 26 | n = 31 | |
Age (years ± SD) | 66.7 ± 10.8 | 67.1 ± 13.1 |
Gender (male/female) | 17/9 | 17/12 |
Race: Caucasian | 26(100%) | 29(100%) |
Time on dialysis (month; median (range)) | 36.5 (4-236) | 36.0(3-132) |
Etiology of ESRD | Â | Â |
  Diabetes | 1(4%) | 5(17%) |
  Nephrosclerosis | 4(15%) | 6(21%) |
  Polycystic | 5(19%) | 3(10%) |
  Chronic glomerulonephritis | 5(19%) | 4(14%) |
  Chronic interstitial | 2(8%) | 2(7%) |
  Postrenal | 4(15%) | 3(10%) |
  Unknown | 5(19%) | 6(21%) |
Cardiovascular history | Â | Â |
  Hypertension | 20(77%) | 22(76%) |
  Diabetes | 2(8%) | 5(17%) |
  Ischemic heart disease | 9(35%) | 10(34%) |
  Stroke or TCI | 3(12%) | 7(24%) |
  Heart failure | 4(15%) | 4(14%) |
Biochemical | Â | Â |
  s-FGF23 (pg/ml (median (range))) | 2952(95-25543) | 2480(117-32650) |
  p-intact PTH (pg/ml ± SD) | 568(246) | 523(175) |
  p-calcium ion (mmol/l ± SD) | 1.16(0.08) | 1.15(0.08) |
  p-phosphate (mmol/l ± SD) | 1.50(0.23) | 1.49(0.27) |
  p-25hydroxyvitamin D2 + D3 (nmol/l ± SD) | 43.4(24.3) | 34.3(22.0) |